المؤلفون: McKenna M; Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ., Ryu Tiger YK; Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ., Rutherford SC; Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY., Evens AM; Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ. Electronic address: andrew.evens@rutgers.edu.

المصدر: Seminars in hematology [Semin Hematol] 2024 Jun 04. Date of Electronic Publication: 2024 Jun 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0404514 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8686 (Electronic) Linking ISSN: 00371963 NLM ISO Abbreviation: Semin Hematol Subsets: MEDLINE

المؤلفون: Rutherford SC; Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Yin J; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN., Pederson LD; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN., Blum KA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Martin P; Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Jung SH; Alliance Statistics and Data Management Center, Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University, Durham, NC., Grant B; Division of Hematology and Oncology, University of Vermont, Burlington, VT., Rosenbaum C; Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Cheson BD; Lymphoma Research Foundation, Bethesda, MD., Bartlett NL; Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO., Mandrekar SJ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN., Leonard JP; Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.

المصدر: Blood advances [Blood Adv] 2024 Mar 26; Vol. 8 (6), pp. 1464-1468.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Follicular*/diagnosis , Lymphoma, Follicular*/therapy, Humans ; Progression-Free Survival ; Rituximab ; Antibodies, Monoclonal, Murine-Derived ; Diagnostic Imaging

المؤلفون: Marullo R; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Rutherford SC; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Revuelta MV; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Zamponi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Culjkovic-Kraljacic B; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Kotlov N; BostonGene Corporation, Waltham, Massachusetts., Di Siervi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Lara-Garcia J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Allan JN; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Ruan J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Furman RR; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Chen Z; Division of Biostatistics, Population Health Sciences Department, Weill Cornell Medicine, New York, New York., Shore TB; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Phillips AA; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Mayer S; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Hsu J; New York University Grossman School of Medicine, New York, New York., van Besien K; University Hospitals Seidman Cancer Center, Cleveland, Ohio., Leonard JP; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Borden KLB; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Inghirami G; Pathology and Laboratory Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Martin P; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Cerchietti L; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York.

المصدر: Cancer research [Cancer Res] 2024 Jan 02; Vol. 84 (1), pp. 101-117.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Non-Hodgkin*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/drug therapy, Humans ; Active Transport, Cell Nucleus ; Karyopherins/metabolism ; Cell Line, Tumor ; Hydrazines/pharmacology ; Receptors, Cytoplasmic and Nuclear/genetics ; Receptors, Cytoplasmic and Nuclear/metabolism ; DNA Damage ; RNA, Messenger/genetics ; RNA, Messenger/metabolism

المؤلفون: Qualls DA; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Lambert N; Department of Medicine, Baylor College of Medicine, Houston, TX., Caimi PF; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Merrill M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Pullarkat P; Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA., Godby RC; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Bond DA; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH., Wehmeyer GT; Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Romancik J; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA., Amoozgar B; Department of Medicine, Washington University School of Medicine, St Louis, MO., Leslie L; Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Abramson JS; Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA., Khurana A; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Nowakowski GS; Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Maddocks K; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH., Rutherford SC; Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Kahl B; Department of Medicine, Washington University School of Medicine, St Louis, MO., Okwali M; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Buege MJ; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Seshan V; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Salles G; Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY.

المصدر: Blood [Blood] 2023 Dec 28; Vol. 142 (26), pp. 2327-2331.

نوع المنشور: Multicenter Study; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/drug therapy, Humans ; Lenalidomide/therapeutic use ; Treatment Outcome ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Ruan J; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Moskowitz A; Memorial Sloan Kettering Cancer Center, New York, NY., Mehta-Shah N; Washington University in St. Louis, St. Louis, MO., Sokol L; Moffitt Cancer Center, Tampa, FL., Chen Z; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Kotlov N; BostonGene Corporation, Waltham, MA., Nos G; BostonGene Corporation, Waltham, MA., Sorokina M; BostonGene Corporation, Waltham, MA., Maksimov V; BostonGene Corporation, Waltham, MA., Sboner A; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Sigouros M; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., van Besien K; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Horwitz S; Memorial Sloan Kettering Cancer Center, New York, NY., Rutherford SC; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Mulvey E; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Revuelta MV; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Xiang J; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Alonso A; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Melnick A; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Elemento O; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Inghirami G; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Leonard JP; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Cerchietti L; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY., Martin P; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.

المصدر: Blood [Blood] 2023 May 04; Vol. 141 (18), pp. 2194-2205.

نوع المنشور: Clinical Trial, Phase II; Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, T-Cell, Peripheral*/pathology, Humans ; Azacitidine/adverse effects ; Doxorubicin ; Prednisone/adverse effects ; Vincristine ; Cyclophosphamide/adverse effects ; Immunologic Factors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Tumor Microenvironment

المؤلفون: Rutherford SC; Weill Department of Medicine, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY., Yin J; Mayo Clinic, Rochester, MN., Pederson L; Mayo Clinic, Rochester, MN., Perez Burbano G; Mayo Clinic, Rochester, MN., LaPlant B; Mayo Clinic, Rochester, MN., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA., Li H; Fred Hutchinson Cancer Research Center, Seattle, WA., LeBlanc ML; Fred Hutchinson Cancer Research Center, Seattle, WA., Kenkre VP; University of Wisconsin, Madison, WI., Hong F; Dana-Farber Cancer Institute, Boston, MA., Blum KA; Emory University, Winship Cancer Institute, Atlanta, GA., Dockter T; Mayo Clinic, Rochester, MN., Martin P; Weill Department of Medicine, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY., Jung SH; Duke University, Raleigh, NC., Grant B; University of Vermont, Burlington, VT., Rosenbaum C; Weill Department of Medicine, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY., Ujjani C; Fred Hutchinson Cancer Research Center, Seattle, WA., Barr PM; University of Rochester, Wilmot Cancer Institute, Rochester, NY., Unger JM; Fred Hutchinson Cancer Research Center, Seattle, WA., Cheson BD; Scientific Advisor, Lymphoma Research Foundation, New York, NY., Bartlett NL; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO., Kahl B; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO., Friedberg JW; University of Rochester, Wilmot Cancer Institute, Rochester, NY., Mandrekar SJ; Mayo Clinic, Rochester, MN., Leonard JP; Weill Department of Medicine, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 10; Vol. 41 (2), pp. 336-342. Date of Electronic Publication: 2022 Jul 05.

نوع المنشور: Multicenter Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Follicular*/drug therapy, United States ; Humans ; Bone Marrow/pathology ; National Cancer Institute (U.S.) ; Survival Analysis ; Biopsy

المؤلفون: Hamid MS; University of Tennessee Health Science Center, Memphis, TN. Electronic address: mhamid2@uthsc.edu., Rutherford SC; Weill Cornell Medicine, New York City, NY., Jang H; Karmanos Cancer Institute, Detroit, MI., Kim S; Karmanos Cancer Institute, Detroit, MI., Patel K; Swedish Cancer Institute, Seattle, WA., Bartlett NL; Washington University Medical University at St. Louis, St. Louis, MO., Malecek MK; Washington University Medical University at St. Louis, St. Louis, MO., Watkins MP; Washington University Medical University at St. Louis, St. Louis, MO., Maddocks KJ; The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH., Bond DA; The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH., Feldman TA; John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ., Magarelli G; John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ., Advani RH; Stanford Cancer Institute at Stanford University, Stanford, CA., Spinner MA; Stanford Cancer Institute at Stanford University, Stanford, CA., Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Shah M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Ahmed S; MD Anderson Cancer Center, Houston, TX., Stephens DM; Huntsman Cancer Institute at University of Utah, Salt Lake City, UT., Allen P; Winship Cancer Institute at Emory University, Atlanta, GA., Tees MT; Colorado Blood Cancer Institute, Denver, CO., Karmali R; Northwestern University, Chicago, IL., Cheson BD; Lombardi Comprehensive Cancer Center, Washington D.C., Yazdy MS; Lombardi Comprehensive Cancer Center, Washington D.C., Strouse C; University of Iowa, Iowa City, IA., Bailey NA; Swedish Cancer Institute, Seattle, WA., Pagel JM; Swedish Cancer Institute, Seattle, WA., Ramchandren R; University of Tennessee Medical Center, Knoxville TN.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Jul; Vol. 22 (7), pp. e435-e442. Date of Electronic Publication: 2021 Dec 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Hodgkin Disease*/diagnostic imaging , Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bleomycin/therapeutic use ; Dacarbazine/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Positron-Emission Tomography/methods ; Vinblastine/therapeutic use

المؤلفون: Marte C; Memorial Sloan Kettering Cancer Center, New York, NY., George LS; Memorial Sloan Kettering Cancer Center, New York, NY., Rutherford SC; Weill Cornell Medicine, New York, NY.; New York Presbyterian, New York, NY., Ouyang DJ; SUNY Downstate Medical Center, New York, NY., Martin P; Weill Cornell Medicine, New York, NY.; New York Presbyterian, New York, NY., Leonard JP; Weill Cornell Medicine, New York, NY.; New York Presbyterian, New York, NY., Trevino KM; Memorial Sloan Kettering Cancer Center, New York, NY.

المصدر: Palliative & supportive care [Palliat Support Care] 2022 Jun; Vol. 20 (3), pp. 328-333.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cambridge University Press Country of Publication: England NLM ID: 101232529 Publication Model: Print Cited Medium: Internet ISSN: 1478-9523 (Electronic) Linking ISSN: 14789515 NLM ISO Abbreviation: Palliat Support Care Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, B-Cell*/complications , Lymphoma, B-Cell*/therapy , Mental Health Services* , Neoplasms* , Psychological Distress*, Humans ; Mental Health ; Quality of Life/psychology ; Stress, Psychological/complications

المؤلفون: Dickinson M; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Briones J; Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau, Spain.; Jose Carreras Leukemia Research Institutes, Autonomous University of Barcelona, Barcelona, Spain., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., González-Barca E; Department of Hematology, Institut Català d'Oncologia, Hospital duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de LLobregat, Barcelona, Spain., Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Cordoba R; Department of Hematology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain., Rutherford SC; Meyer Cancer Center, Division of Hematology and Medical Oncology, Weill Department of Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY., Bournazou E; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY., Labriola-Tompkins E; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY., Franjkovic I; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Chesne E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Brouwer-Visser J; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY., Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Brennan B; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY., Nüesch E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., DeMario M; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY., Rüttinger D; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Kornacker M; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland., Hutchings M; Department of Hematology and.; Phase 1 Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

المصدر: Blood advances [Blood Adv] 2021 Nov 23; Vol. 5 (22), pp. 4762-4770.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Lymphoma, Large B-Cell, Diffuse*/drug therapy, Bridged Bicyclo Compounds, Heterocyclic ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Rituximab/therapeutic use ; Sulfonamides

المؤلفون: Rutherford SC; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA. Electronic address: sar2014@med.cornell.edu., Abramson JS; Department of Haematology and Oncology, Massachusetts General Hospital, Boston, MA, USA., Bartlett NL; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA., Barta SK; Division of Haematology and Oncology, University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA, USA., Khan N; Fox Chase Cancer Center, Philadelphia, PA, USA., Joyce R; Beth-Israel Deaconess Medical Center, Boston, MA, USA., Maddocks K; James Cancer Hospital, Ohio State University, Columbus, OH, USA., Ali-Shaw T; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA., Senese S; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA., Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin J; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Leonard JP; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA.

المصدر: The Lancet. Haematology [Lancet Haematol] 2021 Nov; Vol. 8 (11), pp. e818-e827. Date of Electronic Publication: 2021 Oct 08.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use , Lymphoma, B-Cell/*drug therapy , Sulfonamides/*therapeutic use, Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Female ; Humans ; Lymphoma, B-Cell/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Vincristine/therapeutic use

SCR Protocol: EPOCH protocol